TY  - JOUR
A1  - Eichenauer, Dennis Alexander
A1  - Bühnen, Ina
A1  - Kreissl, Stefanie
A1  - Goergen, Helen
A1  - Fuchs, Michael
A1  - Tresckow, Bastian von
A1  - Rosenwald, Andreas
A1  - Klapper, Wolfram
A1  - Hansmann, Martin-Leo
A1  - Möller, Peter
A1  - Bernd, Heinz-Wolfram
A1  - Feller, Alfred C.
A1  - Engert, Andreas
A1  - Borchmann, Peter
A1  - Hartmann, Sylvia
T1  - Histopathological growth patterns in patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group
T2  - British journal of haematology
N2  - We retrospectively investigated histopathological growth patterns in individuals with advanced nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) treated within the randomized HD18 study. In all, 35/60 patients (58%) presented with atypical growth patterns. Patients with atypical growth patterns more often had stage IV disease (P = 0·0354) and splenic involvement (P = 0·0048) than patients with typical growth patterns; a positive positron emission tomography after two cycles of chemotherapy (PET-2) tended to be more common (P = 0·1078). Five-year progression-free survival [hazard ratio (HR) = 0·86; 95% confidence interval (CI) = 0·49–1·47] and overall survival (HR = 0·85; 95% CI = 0·49–1·51) did not differ between the groups after study treatment with PET-2-guided escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone). Thus, advanced NLPHL is often associated with atypical growth patterns but their prognostic impact is compensated by PET-2-guided escalated BEACOPP.
KW  - nodular lymphocyte-predominant Hodgkin lymphoma
KW  - histopathological growth pattern
KW  - BEACOPP
KW  - interim positron emissiontomography
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/63955
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-639552
SN  - 1365-2141
N1  - SH is supported by the Deutsche Forschungsgemeinschaft (grant HA6145/3-1).
VL  - 196
IS  - 1
SP  - 99
EP  - 104
PB  - Wiley-Blackwell
CY  - Oxford [u.a.]
ER  -